Brand-name Wegovy can cost up to $1,350 a month without insurance, but several strategies can bring that number down significantly. Some options cut the price by more than half, while others may get you the medication for free. Here’s what’s actually available right now.
The Manufacturer Savings Offer
Novo Nordisk, the company that makes Wegovy, runs a savings program through its NovoCare website that’s open to people without insurance, people whose insurance doesn’t cover the drug, and people who choose to pay out of pocket. Through this program, the injectable pen starts at $199 per month for the lowest dose (0.25 mg), and the newer oral tablet is $149 per month for the 1.5 mg strength. Prices vary by dose, so expect costs to shift as your provider increases your dosage over the first several months of treatment.
This is the single easiest discount to access. You don’t need to meet income requirements or jump through lengthy application processes. You can sign up on the NovoCare website or ask your prescriber’s office to help you enroll.
Warehouse Pharmacy Pricing
Costco, Sam’s Club, and the grocery chain Hy-Vee began offering Wegovy at $499 a month as of late 2025. That’s a steep discount from the $1,350 list price, though still more expensive than the manufacturer savings offer for lower doses. These warehouse prices don’t require a membership at every location (pharmacy laws in many states require stores to fill prescriptions for non-members), so it’s worth calling your nearest location to confirm.
If you’re comparing options, check whether the manufacturer savings program or the warehouse price is lower for your specific prescribed dose. At higher maintenance doses, warehouse pricing may be competitive with or even better than the savings card, depending on how the tiered pricing works out.
Free Wegovy Through Patient Assistance
Novo Nordisk also operates a Patient Assistance Program (PAP) that provides Wegovy at no cost to qualifying patients. The income threshold is generous: your total household income must fall at or below 400% of the federal poverty level. For a single person in 2025, that’s roughly $62,000 a year. For a family of four, it’s around $127,000. These numbers update annually, and the NeedyMeds website publishes the current federal poverty level guidelines.
You’ll need to be uninsured or underinsured to qualify. Medicare beneficiaries have a separate pathway with a stricter income cap of 150% of the federal poverty level, and they must show proof that they were denied Part D Extra Help before applying. The application process involves paperwork from both you and your prescriber, and approval can take a few weeks, but if you qualify, this is the best deal available: the medication is completely free.
What Happened to Compounded Semaglutide
During the Wegovy shortage, compounding pharmacies legally produced their own versions of semaglutide (Wegovy’s active ingredient) at dramatically lower prices, sometimes $150 to $300 a month. Many readers searching for cheap Wegovy alternatives will have heard about this option. The landscape has changed.
Semaglutide no longer appears on the FDA’s drug shortage list. This matters because the legal framework that allowed large-scale compounding (called 503B outsourcing) requires a drug to either be on the shortage list or on a separate approved bulk substances list. Semaglutide is on neither. Individual compounding pharmacies operating under section 503A of federal law can still fill patient-specific prescriptions, but the FDA has signaled that compounded products with the same active ingredient, same route of administration, and same or similar strength as a commercially available drug may be considered “essentially a copy,” which is restricted under federal law.
In practical terms, the supply of compounded semaglutide is shrinking. Some compounding pharmacies are still operating, particularly those compounding under 503A with individual prescriptions, but this is a legally gray and rapidly shifting space. If you’re currently using compounded semaglutide, talk with your provider about a transition plan.
Telehealth Platforms and Subscription Programs
Online weight management platforms like Ro, Hims, Found, and others offer subscription-based programs that bundle a prescriber visit with medication management. Monthly fees for the consultation portion typically range from $30 to $150 depending on the platform, but you still pay for the medication itself on top of that. Some platforms negotiate their own drug pricing or partner with pharmacies to offer bundled rates.
The value here isn’t necessarily a cheaper drug. It’s convenience and potentially lower prescriber fees compared to an in-office visit. If you already have a prescriber willing to write the prescription, a telehealth subscription may not save you anything on the medication cost. But if you need a new prescription and want to avoid a full-price office visit, these platforms can reduce the total out-of-pocket burden when combined with the manufacturer savings offer or warehouse pricing.
Using an HSA or FSA to Pay
If you have access to a Health Savings Account or Flexible Spending Account through a current or former employer, Wegovy qualifies as a reimbursable medical expense when prescribed by a physician to treat a diagnosed condition like obesity, diabetes, or heart disease. The IRS is specific on this point: weight loss expenses only count if they treat a physician-diagnosed disease, not if they’re pursued for general health or cosmetic reasons.
This doesn’t reduce the sticker price, but it lets you pay with pre-tax dollars, which effectively saves you whatever your marginal tax rate is. For someone in the 22% federal bracket, that’s like getting a 22% discount (plus any state income tax savings). If you’re planning to use this approach, keep your prescription documentation and any letter from your doctor confirming the medical diagnosis. You may also be able to deduct Wegovy costs on your federal tax return if your total medical expenses exceed 7.5% of your adjusted gross income.
When Generic Semaglutide Might Arrive
Novo Nordisk’s U.S. patent on semaglutide doesn’t expire until 2032, so a true FDA-approved generic is likely years away. In China, where the patent expires in 2026, several pharmaceutical companies are preparing generic launches between 2025 and 2027. Those products won’t be legally available in the U.S., but their existence may eventually put pressure on global pricing.
For now, the most realistic path to affordable Wegovy without insurance is layering the strategies above: apply for the Patient Assistance Program if your income qualifies, use the manufacturer savings offer if it doesn’t, compare warehouse pharmacy pricing at higher doses, and pay with pre-tax health account dollars when possible.